No two patients respond to medicines in exactly the same way. A drug that works effectively for one person may cause side effects in another or fail to deliver the desired benefit. For decades, prescribing has relied on population averages, with doses and drug choices based on clinical trials conducted across broad groups. Pharmacogenomics is changing this approach. By examining how an individual’s genetic makeup influences their response to medicines, this field aims to personalise prescribing and improve outcomes.

As genomic technologies become more accessible, pharmacogenomics is moving closer to routine clinical practice, offering the prospect of safer and more effective treatment.

Understanding genetic variation

Genes influence how the body absorbs, metabolises and eliminates medicines. Variations in specific genes can affect enzymes responsible for breaking down drugs in the liver. Some individuals metabolise certain medicines very quickly, reducing effectiveness, while others process them slowly, increasing the risk of toxicity.

Pharmacogenomic testing identifies these variations before a medicine is prescribed. With this information, clinicians can adjust the dose or select an alternative therapy more suited to the patient’s genetic profile. This approach aims to reduce adverse drug reactions, which remain a significant cause of hospital admissions.

Applications in everyday care

Pharmacogenomics is already being applied in several therapeutic areas. In oncology, genetic testing helps determine which patients are most likely to benefit from targeted cancer therapies. In cardiology, variations in genes involved in drug metabolism can influence how patients respond to common blood thinners.

Mental health is another area of growing interest. Antidepressants and antipsychotic medications can vary widely in their effects from person to person. Genetic insights may help guide clinicians towards treatments that are more likely to work and less likely to cause unwanted side effects.

By reducing trial-and-error prescribing, pharmacogenomics has the potential to improve patient experience and shorten the time it takes to find an effective treatment.

Improving safety and efficiency

Adverse drug reactions are a major burden on healthcare systems. By identifying individuals at higher risk of side effects, pharmacogenomic testing could prevent avoidable harm. This not only improves patient safety but may also reduce costs associated with hospital admissions and additional treatments.

In the long term, integrating pharmacogenomic data into electronic health records could streamline decision-making. When a clinician prescribes a medicine, alerts could flag potential genetic concerns automatically, supporting more informed choices at the point of care.

Challenges to implementation

Despite its promise, widespread adoption of pharmacogenomics faces practical and ethical challenges. Testing requires infrastructure for genomic analysis and secure data storage. Interpreting results also demands specialised knowledge, and clinicians must be supported with clear guidelines and training.

Cost remains a consideration, although the price of genetic sequencing has fallen dramatically over the past decade. Demonstrating cost effectiveness in routine care will be essential for broader integration within publicly funded systems.

Privacy and consent are equally important. Genetic data is sensitive, and robust safeguards are needed to ensure confidentiality. Patients must understand how their data will be used and stored.

The UK’s potential

The UK’s investment in genomics research provides a strong platform for advancing pharmacogenomics. National initiatives focused on integrating genomic medicine into the NHS have already begun to lay the groundwork for personalised care.

Collaborations between academic institutions, healthcare providers and biotechnology companies are driving research into how genetic variation affects drug response. As evidence grows, the UK has the opportunity to embed pharmacogenomics more fully into clinical pathways.

Looking ahead

The future of pharmacogenomics lies in integration. Rather than ordering separate genetic tests for each medication, patients may one day have a comprehensive genomic profile stored securely within their health record. This information could guide prescribing decisions throughout their lifetime.

As artificial intelligence tools evolve, they may assist clinicians in interpreting complex genetic information and combining it with other health data. The convergence of genomics, digital health and personalised medicine could reshape prescribing practices fundamentally.

Conclusion

Pharmacogenomics represents a significant step towards truly personalised medicine. By tailoring treatments to an individual’s genetic profile, healthcare providers can aim for greater effectiveness and improved safety. While challenges remain around infrastructure, cost and data governance, progress is steady.

For patients, the promise is clear: fewer side effects, more targeted therapies and faster access to treatments that work. For healthcare systems, the potential benefits include reduced waste and improved efficiency. As genomic technologies continue to advance, pharmacogenomics may become an integral part of everyday clinical practice, bringing precision to prescribing in ways that were once unimaginable.